Low-Dose Dextromethorphan for the Treatment of Fibromyalgia Pain: Results from a Longitudinal, Single-Blind, Placebo-Controlled Pilot Trial

References

• Wolfe F, Clauw DJ, Fitzcharles MA, et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum. 2016;46(3):319–329. doi:10.1016/j.semarthrit.2016.08.012
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles M-A, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010;62(5):600–610. doi:10.1002/acr.20140
   PubMed Web of Science ®Google Scholar
• Staud R, Cannon RC, Mauderli AP, Robinson ME, Price DD, Vierck CJ. Temporal summation of pain from mechanical stimulation of muscle tissue in normal controls and subjects with fibromyalgia syndrome. Pain. 2003;102(1–2):87–95. doi:10.1016/s0304-3959(02)00344-5
   PubMed Web of Science ®Google Scholar
• Staud R, Craggs JG, Perlstein WM, Robinson ME, Price DD. Brain activity associated with slow temporal summation of C-fiber evoked pain in fibromyalgia patients and healthy controls. Eur J Pain. 2008;12(8):1078–1089. doi:10.1016/j.ejpain.2008.02.002
   PubMed Web of Science ®Google Scholar
• Staud R, Robinson ME, Price DD. Temporal summation of second pain and its maintenance are useful for characterizing widespread central sensitization of fibromyalgia patients. J Pain. 2007;8(11):893–901. doi:10.1016/j.jpain.2007.06.006
   PubMed Web of Science ®Google Scholar
• Staud R, Vierck CJ, Cannon RL, Mauderli AP, Price DD. Abnormal sensitization and temporal summation of second pain (wind-up) in patients with fibromyalgia syndrome. Pain. 2001;91(1–2):165–175. doi:10.1016/S0304-3959(00)00432-2
   PubMed Web of Science ®Google Scholar
• Staud R, Weyl EE, Riley JL, Fillingim RB. Slow temporal summation of pain for assessment of central pain sensitivity and clinical pain of fibromyalgia patients. PLoS One. 2014;9(2):e89086. doi:10.1371/journal.pone.0089086
   PubMed Web of Science ®Google Scholar
• Cagnie B, Coppieters I, Denecker S, Six J, Danneels L, Meeus M. Central sensitization in fibromyalgia? A systematic review on structural and functional brain MRI. Semin Arthritis Rheum. 2014;44(1):68–75. doi:10.1016/j.semarthrit.2014.01.001
   PubMed Web of Science ®Google Scholar
• Lund I, Lundeberg T, Carleson J, Sönnerfors H, Uhrlin B, Svensson E. Corticotropin releasing factor in urine–a possible biochemical marker of fibromyalgia. Responses to massage and guided relaxation. Neurosci Lett. 2006;403(1–2):166–171. doi:10.1016/j.neulet.2006.04.038
   Web of Science ®Google Scholar
• McLean SA, Williams DA, Stein PK, et al. Cerebrospinal fluid corticotropin-releasing factor concentration is associated with pain but not fatigue symptoms in patients with fibromyalgia. Neuropsychopharmacology. 2006;31(12):2776–2782. doi:10.1038/sj.npp.1301200
   PubMed Web of Science ®Google Scholar
• Becker S, Schweinhardt P. Dysfunctional neurotransmitter systems in fibromyalgia, their role in central stress circuitry and pharmacological actions on these systems. Pain Res Treat. 2012;2012:741746. doi:10.1155/2012/741746
   PubMedGoogle Scholar
• Stahl SM. Fibromyalgia–pathways and neurotransmitters. Hum Psychopharmacol. 2009;24(Suppl 1):S11–17. doi:10.1002/hup.1029
   PubMed Web of Science ®Google Scholar
• Harris RE. Elevated excitatory neurotransmitter levels in the fibromyalgia brain. Arthritis Res Ther. 2010;12(5):141. doi:10.1186/ar3136
   Web of Science ®Google Scholar
• Russell IJ, Orr MD, Littman B, et al. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis Rheum. 1994;37(11):1593–1601. doi:10.1002/art.1780371106
   PubMed Web of Science ®Google Scholar
• Bidari A, Ghavidel-Parsa B, Rajabi S, Sanaei O, Toutounchi M. The acute effect of maximal exercise on plasma beta-endorphin levels in fibromyalgia patients. Korean J Pain. 2016;29(4):249–254. doi:10.3344/kjp.2016.29.4.249
   Web of Science ®Google Scholar
• Cording M, Derry S, Phillips T, Moore RA, Wiffen PJ. Milnacipran for pain in fibromyalgia in adults. Cochrane Database Syst Rev. 2015;2015(10):Cd008244.
   Google Scholar
• Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med. 2002;112(3):191–197. doi:10.1016/S0002-9343(01)01089-0
   PubMed Web of Science ®Google Scholar
• Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev. 2015;2015(6):Cd011735.
   Google Scholar
• Harris RE, Clauw DJ, Scott DJ, McLean SA, Gracely RH, Zubieta JK. Decreased central mu-opioid receptor availability in fibromyalgia. J Neurosci. 2007;27(37):10000–10006. doi:10.1523/JNEUROSCI.2849-07.2007
   PubMed Web of Science ®Google Scholar
• Rao SG, Clauw DJ. The management of fibromyalgia. Drugs Today. 2004;40(6):539–554. doi:10.1358/dot.2004.40.6.850485
   PubMed Web of Science ®Google Scholar
• Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91(5):640–648. doi:10.1016/j.mayocp.2016.02.002
   PubMed Web of Science ®Google Scholar
• Fitzcharles M-A, Faregh N, Ste-Marie PA, Shir Y. Opioid use in fibromyalgia is associated with negative health related measures in a prospective cohort study. Pain Res Treat. 2013;2013:898493. doi:10.1155/2013/898493
   PubMedGoogle Scholar
• Peng X, Robinson RL, Mease P, et al. Long-term evaluation of opioid treatment in fibromyalgia. Clin J Pain. 2015;31(1):7–13. doi:10.1097/AJP.0000000000000079
   PubMed Web of Science ®Google Scholar
• Albrecht DS, Forsberg A, Sandström A, et al. Brain glial activation in fibromyalgia - a multi-site positron emission tomography investigation. Brain Behav Immun. 2019;75:72–83. doi:10.1016/j.bbi.2018.09.018
   PubMed Web of Science ®Google Scholar
• Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci. 2005;8(6):752–758. doi:10.1038/nn1472
   PubMed Web of Science ®Google Scholar
• Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol. 2009;27:119–145. doi:10.1146/annurev.immunol.021908.132528
   PubMed Web of Science ®Google Scholar
• D’Ambrosi N, Finocchi P, Apolloni S, et al. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J Immunol. 2009;183(7):4648–4656. doi:10.4049/jimmunol.0901212
   Web of Science ®Google Scholar
• Lynch MA. The multifaceted profile of activated microglia. Mol Neurobiol. 2009;40(2):139–156.
   PubMed Web of Science ®Google Scholar
• Sharma M, Arbabzada N, Flood PM. Mechanism underlying beta2-AR agonist-mediated phenotypic conversion of LPS-activated microglial cells. J Neuroimmunol. 2019;332:37–48. doi:10.1016/j.jneuroim.2019.03.017
   PubMed Web of Science ®Google Scholar
• Bianchi M, Sacerdote P, Ricciardi-Castagnoli P, Mantegazza P, Panerai AE. Central effects of tumor necrosis factor alpha and interleukin-1 alpha on nociceptive thresholds and spontaneous locomotor activity. Neurosci Lett. 1992;148(1–2):76–80. doi:10.1016/0304-3940(92)90808-K
   Web of Science ®Google Scholar
• Aaron LA, Burke MM, Buchwald D. Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder. Arch Intern Med. 2000;160(2):221–227. doi:10.1001/archinte.160.2.221
   PubMed Web of Science ®Google Scholar
• Dantzer R. Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci. 2001;933:222–234. doi:10.1111/j.1749-6632.2001.tb05827.x
   PubMed Web of Science ®Google Scholar
• Dantzer R. Cytokine-induced sickness behaviour: a neuroimmune response to activation of innate immunity. Eur J Pharmacol. 2004;500(1–3):399–411. doi:10.1016/j.ejphar.2004.07.040
   PubMed Web of Science ®Google Scholar
• Dantzer R, Bluthe RM, Gheusi G, et al. Molecular basis of sickness behavior. Ann N Y Acad Sci. 1998;856:132–138. doi:10.1111/j.1749-6632.1998.tb08321.x
   PubMed Web of Science ®Google Scholar
• Poon DC, Ho YS, Chiu K, Wong HL, Chang RC. Sickness: from the focus on cytokines, prostaglandins, and complement factors to the perspectives of neurons. Neurosci Biobehav Rev. 2015;57:30–45. doi:10.1016/j.neubiorev.2015.07.015
   PubMed Web of Science ®Google Scholar
• Patten DK, Schultz BG, Berlau DJ. The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy. 2018;38(3):382–389. doi:10.1002/phar.2086
   PubMed Web of Science ®Google Scholar
• Younger J, Mackey S. Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study. Pain Medicine. 2009;10(4):663–672. doi:10.1111/j.1526-4637.2009.00613.x
   PubMed Web of Science ®Google Scholar
• Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5:2. doi:10.3390/biomedicines5020016
   Web of Science ®Google Scholar
• Cheng W, Li Y, Hou X, et al. Determining the neuroprotective effects of dextromethorphan in lipopolysaccharidestimulated BV2 microglia. Mol Med Rep. 2015;11(2):1132–1138. doi:10.3892/mmr.2014.2794
   Web of Science ®Google Scholar
• Lee J-H, Choi S-H, Shin T-J, et al. Effect of dextromethorphan on human Kv1.3 channel activity: involvement of C-type inactivation. Eur J Pharmacol. 2011;651(1):122–127. doi:10.1016/j.ejphar.2010.10.091
   Web of Science ®Google Scholar
• Li G, Cui G, Tzeng N-S, et al. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 2005;19(6):489–496. doi:10.1096/fj.04-2555com
   Web of Science ®Google Scholar
• Liu Y, Qin L, Li G, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 2003;305(1):212–218. doi:10.1124/jpet.102.043166
   Web of Science ®Google Scholar
• Song J-H, Yeh JZ. Dextromethorphan inhibition of voltage-gated proton currents in BV2 microglial cells. Neurosci Lett. 2012;516(1):94–98. doi:10.1016/j.neulet.2012.03.065
   Web of Science ®Google Scholar
• Zhang W, Qin L, Wang T, et al. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J. 2005;19(3):395–397. doi:10.1096/fj.04-1586fje
   Web of Science ®Google Scholar
• Cohen SP, Verdolin MH, Chang AS, Kurihara C, Morlando BJ, Mao J. The intravenous ketamine test predicts subsequent response to an oral dextromethorphan treatment regimen in fibromyalgia patients. J Pain. 2006;7(6):391–398. doi:10.1016/j.jpain.2005.12.010
   PubMed Web of Science ®Google Scholar
• Journey JD, Stern E. Dextromethorphan Toxicity. Treasure Island (FL): StatPearls Publishing; 2019.
   Google Scholar
• Chechneva OV, Mayrhofer F, Daugherty DJ, Pleasure DE, Hong JS, Deng W. Low dose dextromethorphan attenuates moderate experimental autoimmune encephalomyelitis by inhibiting NOX2 and reducing peripheral immune cells infiltration in the spinal cord. Neurobiol Dis. 2011;44(1):63–72. doi:10.1016/j.nbd.2011.06.004
   Web of Science ®Google Scholar
• Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry. 2007;4(7):28–37.
   PubMedGoogle Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.
   PubMedGoogle Scholar
• Stern AF. The Hospital anxiety and depression scale. Occup Med (Chic Ill). 2014;64(5):393–394. doi:10.1093/occmed/kqu024
   PubMed Web of Science ®Google Scholar
• Younger J, Gandhi V, Hubbard E, Mackey S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials. 2012;9(6):767–776. doi:10.1177/1740774512465064
   PubMed Web of Science ®Google Scholar
• Skinner HA. Drug Use Questionnaire (DAST-20). Addiction Research Foundation; 1982.
   Google Scholar
• Barnhart JW, Massad EN. Determination of dextromethorphan in serum by gas chromatography. J Chromatogr. 1979;163(4):390–395. doi:10.1016/S0378-4347(00)81642-4
   PubMed Web of Science ®Google Scholar
• Marier JF, Deschenes JL, Hage A, et al. Enhancing the uptake of dextromethorphan in the CNS of rats by concomitant administration of the P-gp inhibitor verapamil. Life Sci. 2005;77(23):2911–2926. doi:10.1016/j.lfs.2005.04.025
   PubMed Web of Science ®Google Scholar
• Perry PJ, Fredriksen K, Chew S, et al. The effects of dextromethorphan on driving performance and the standardized field sobriety test. J Forensic Sci. 2015;60(5):1258–1262. doi:10.1111/1556-4029.12833
   Web of Science ®Google Scholar
• Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ. Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans. Drug Alcohol Depend. 2013;128(3):206–213. doi:10.1016/j.drugalcdep.2012.08.025
   Web of Science ®Google Scholar
• Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR. High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacology. 2012;223(1):1–15. doi:10.1007/s00213-012-2680-6
   PubMed Web of Science ®Google Scholar
• Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clin Drug Investig. 2012;32(8):e1–15. doi:10.1007/BF03261905
   Google Scholar
• de la Coba P, Bruehl S, Moreno-Padilla M, Reyes Del Paso GA. Responses to slowly repeated evoked pain stimuli in fibromyalgia patients: evidence of enhanced pain sensitization. Pain Medicine. 2017;18(9):1778–1786. doi:10.1093/pm/pnw361
   PubMed Web of Science ®Google Scholar
• O’Brien AT, Deitos A, Trinanes Pego Y, Fregni F, Carrillo-de-la-Pena MT. Defective endogenous pain modulation in fibromyalgia: a meta-analysis of temporal summation and conditioned pain modulation paradigms. J Pain. 2018;19(8):819–836. doi:10.1016/j.jpain.2018.01.010
   PubMed Web of Science ®Google Scholar
• Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain. 2002;99(1–2):49–59. doi:10.1016/S0304-3959(02)00053-2
   PubMed Web of Science ®Google Scholar
• Davies SN, Lodge D. Evidence for involvement of N-methylaspartate receptors in ‘wind-up’ of class 2 neurones in the dorsal horn of the rat. Brain Res. 1987;424(2):402–406. doi:10.1016/0006-8993(87)91487-9
   PubMed Web of Science ®Google Scholar
• Dickenson AH, Sullivan AF. Evidence for a role of the NMDA receptor in the frequency dependent potentiation of deep rat dorsal horn nociceptive neurones following C fibre stimulation. Neuropharmacology. 1987;26(8):1235–1238. doi:10.1016/0028-3908(87)90275-9
   PubMed Web of Science ®Google Scholar
• Parada CA, Luccarini P, Woda A. Effect of an NMDA receptor antagonist on the wind-up of neurons in the trigeminal oralis subnucleus. Brain Res. 1997;761(2):313–320. doi:10.1016/S0006-8993(97)00355-7
   Web of Science ®Google Scholar
• Fayed N, Olivan-Blazquez B, Herrera-Mercadal P, et al. Changes in metabolites after treatment with memantine in fibromyalgia. A double-blind randomized controlled trial with magnetic resonance spectroscopy with a 6-month follow-up. CNS Neurosci Ther. 2014;20(11):999–1007. doi:10.1111/cns.12314
   PubMed Web of Science ®Google Scholar
• Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85(3):483–491. doi:10.1016/S0304-3959(99)00308-5
   PubMed Web of Science ®Google Scholar
• Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15(9):942–949. doi:10.1016/j.ejpain.2011.03.008
   PubMed Web of Science ®Google Scholar
• Olivan-Blazquez B, Herrera-Mercadal P, Puebla-Guedea M, et al. Efficacy of memantine in the treatment of fibromyalgia: a double-blind, randomised, controlled trial with 6-month follow-up. Pain. 2014;155(12):2517–2525. doi:10.1016/j.pain.2014.09.004
   PubMed Web of Science ®Google Scholar
• Sorensen J, Bengtsson A, Backman E, Henriksson KG, Bengtsson M. Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand J Rheumatol. 1995;24(6):360–365. doi:10.3109/03009749509095181
   PubMed Web of Science ®Google Scholar